LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

LLY

710.61

+0.3%↑

JNJ

179.04

+0.08%↑

ABBV

210.25

+0.41%↑

UNH

306.92

+1.28%↑

AZN

80.93

+0.65%↑

Inicio・Lista de Acciones・Essa Pharma Inc

Essa Pharma Inc

Cerrado

1.92

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.83

Máximo

1.92

Métricas clave
By Trading Economics
Ingresos	2.4M -4M
BPA	-0.14
Empleados	35
EBITDA	2.2M -6.4M

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	5.7M 90M
Apertura anterior	1.92
Cierre anterior	1.92

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

1.7 / 1.72 Soporte y Resistencia

Essa Pharma Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 ago 2025, 23:09 UTC

Adquisiciones, fusiones, absorciones

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 4th Update

22 ago 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

Agreement Could Also Lead to Deeper Collaboration Between CSX, BNSF

22 ago 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

Some Analysts Say Agreement Suggests Lack of Confidence in Merger

22 ago 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

CSX, BNSF Intermodal Pact Draws Competing Views on Merger Possibility

22 ago 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

CSX, BNSF Pact Sparks Debate on Whether Another Rail Merger Is Approaching -- Analysis

22 ago 2025, 22:02 UTC

Adquisiciones, fusiones, absorciones

Pact Could Show Regulators That Transcontinental Service Can Come Without Merger

22 ago 2025, 21:23 UTC

Charlas de Mercado

Moody's Lowers Outlook on Austria to Negative From Stable -- Market Talk

22 ago 2025, 21:18 UTC

Charlas de Mercado

US Economic Growth Seen Slowing This Year -- Market Talk

22 ago 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

U.S. Takes 10% Stake in Intel -- Barrons.com

22 ago 2025, 21:03 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

22 ago 2025, 21:03 UTC

Charlas de Mercado

Mexican Stocks Close At Record High -- Market Talk

22 ago 2025, 20:58 UTC

Charlas de Mercado

US General Government Deficit Expected to Rise in 2026, 2027 -- Market Talk

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: Government's Investment in Intel Will Be a Passive Ownership, With No Bd Representation or Other Governance or Info Rights >INTC

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: Government Also Agrees to Vote With the Company's Bd of Directors on Matters Requiring Shareholder Approval, With Limited Exceptions >INTC

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: Government Equity Stake Will Be Funded by Remaining $5.7B in Grants Previously Awarded, But Not Yet Paid, Under U.S. CHIPS and Science Act and $3.2B Awarded as Part of Secure Enclave Program >INTC

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: Government Agrees to Purchase 433.3M Primary Shrs of Intel Common Stk at a Price of $20.47 per Shr, Equivalent to a 9.9% Stake in Co >INTC

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: U.S. Government to Make $8.9B Investment in Intel Common Stk as Co Builds Upon Its More Than $100B Expansion of Resilient Semiconductor Supply Chain >INTC

22 ago 2025, 20:57 UTC

Adquisiciones, fusiones, absorciones

Intel: Intel and Trump Admin Reach Historic Agreement to Accelerate Amer Technology and Manufacturing Leadership

22 ago 2025, 20:56 UTC

Ganancias

These Stocks Moved the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 ago 2025, 20:55 UTC

Ganancias

These Stocks Are Moving the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

22 ago 2025, 20:50 UTC

Charlas de Mercado

Ganancias

Tech, Media & Telecom Roundup: Market Talk

22 ago 2025, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

22 ago 2025, 20:41 UTC

Adquisiciones, fusiones, absorciones

U.S. Has 10% Stake in Intel, Lutnick Says -- Barrons.com

22 ago 2025, 20:24 UTC

Adquisiciones, fusiones, absorciones

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 3rd Update

22 ago 2025, 20:16 UTC

Adquisiciones, fusiones, absorciones

CSX and Warren Buffett's BNSF Made News. Why Investors Are Disappointed. -- Barrons.com

22 ago 2025, 19:19 UTC

Charlas de Mercado

Boeing to Restart Talks With Defense Workers' Union Monday -- Market Talk

22 ago 2025, 19:10 UTC

Charlas de Mercado

Oil Futures Gain as Russia-Ukraine Peace Seems Distant -- Market Talk

22 ago 2025, 19:06 UTC

Charlas de Mercado

U.S. Natural Gas Extends Losses as Summer Nears an End -- Market Talk

22 ago 2025, 19:03 UTC

Charlas de Mercado

Lower Borrowing Rates Elusive Even if Fed Cuts -- Market Talk

22 ago 2025, 18:52 UTC

Adquisiciones, fusiones, absorciones

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 2nd Update

Comparación entre iguales

Cambio de precio

Essa Pharma Inc Esperado

Consenso

By TipRanks

0 ratings

Comprar

Mantener

Vender

De acuerdo con 0 analistas que ofrecen calificaciones bursátiles a para Essa Pharma Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.7 / 1.72Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Essa Pharma Inc

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.